Prognostic impact of oral anticoagulation therapy and atrial fibrillation in patients with type B acute aortic dissection
© 2024 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society..
Background: The prognostic impact of atrial fibrillation (AF) and oral anticoagulation (OAC) therapy in patients with type B acute aortic dissection (AAD) remains unclear. Therefore, we investigated the prognostic impact of AF and OAC therapy in patients with type B AAD.
Methods: Consecutive patients diagnosed with AAD were included in this single-center, retrospective study. Patients with type B AAD were selected from the study population and divided into three groups: AF(+)/OAC(+), AF(+)/OAC(-), and AF(-)/OAC(-). The primary end point was major adverse cardiovascular and cerebrovascular events (MACCE), including all-cause death, progressive aortic events, cerebral infarction, and organ malperfusion.
Results: In total, 139 patients diagnosed with type B AAD were analyzed. AF was observed in 27 patients (19%). Among them, 13 patients (9%) received OAC therapy for AF. MACCE occurred in 32 patients (23%) during the observation period: all-cause death in four patients, progressive aortic events in 24 patients, cerebral infarction events in two patients, and malperfusion events in two patients. The incidence of MACCE was higher in the AF(+)/OAC(+) group than in the AF(+)/OAC(-) group (hazard ratio[HR]: 3.875; 95% confidence interval [CI]: 1.153-17.496). In contrast, there was no significant difference in the incidence of MACCE between the AF(+)/OAC(-) and AF(-)/OAC(-) groups (HR: 1.001, 95% CI: 0.509-1.802).
Conclusion: Among patients with type B AAD, the use of OAC for AF was associated with a higher risk of MACCE.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Journal of arrhythmia - 40(2024), 2 vom: 28. Apr., Seite 297-305 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ishizue, Naruya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute aortic dissection |
|---|
| Anmerkungen: |
Date Revised 09.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/joa3.13020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370762622 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370762622 | ||
| 003 | DE-627 | ||
| 005 | 20240409233040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240408s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/joa3.13020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM370762622 | ||
| 035 | |a (NLM)38586850 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ishizue, Naruya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic impact of oral anticoagulation therapy and atrial fibrillation in patients with type B acute aortic dissection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society. | ||
| 520 | |a Background: The prognostic impact of atrial fibrillation (AF) and oral anticoagulation (OAC) therapy in patients with type B acute aortic dissection (AAD) remains unclear. Therefore, we investigated the prognostic impact of AF and OAC therapy in patients with type B AAD | ||
| 520 | |a Methods: Consecutive patients diagnosed with AAD were included in this single-center, retrospective study. Patients with type B AAD were selected from the study population and divided into three groups: AF(+)/OAC(+), AF(+)/OAC(-), and AF(-)/OAC(-). The primary end point was major adverse cardiovascular and cerebrovascular events (MACCE), including all-cause death, progressive aortic events, cerebral infarction, and organ malperfusion | ||
| 520 | |a Results: In total, 139 patients diagnosed with type B AAD were analyzed. AF was observed in 27 patients (19%). Among them, 13 patients (9%) received OAC therapy for AF. MACCE occurred in 32 patients (23%) during the observation period: all-cause death in four patients, progressive aortic events in 24 patients, cerebral infarction events in two patients, and malperfusion events in two patients. The incidence of MACCE was higher in the AF(+)/OAC(+) group than in the AF(+)/OAC(-) group (hazard ratio[HR]: 3.875; 95% confidence interval [CI]: 1.153-17.496). In contrast, there was no significant difference in the incidence of MACCE between the AF(+)/OAC(-) and AF(-)/OAC(-) groups (HR: 1.001, 95% CI: 0.509-1.802) | ||
| 520 | |a Conclusion: Among patients with type B AAD, the use of OAC for AF was associated with a higher risk of MACCE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute aortic dissection | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a cardiovascular event | |
| 650 | 4 | |a oral anticoagulation therapy | |
| 700 | 1 | |a Fukaya, Hidehira |e verfasserin |4 aut | |
| 700 | 1 | |a Oikawa, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Nobuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ogiso, Sho |e verfasserin |4 aut | |
| 700 | 1 | |a Murayama, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Hironori |e verfasserin |4 aut | |
| 700 | 1 | |a Kishihara, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Niwano, Shinichi |e verfasserin |4 aut | |
| 700 | 1 | |a Ako, Junya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of arrhythmia |d 2014 |g 40(2024), 2 vom: 28. Apr., Seite 297-305 |w (DE-627)NLM245858962 |x 1880-4276 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2024 |g number:2 |g day:28 |g month:04 |g pages:297-305 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/joa3.13020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2024 |e 2 |b 28 |c 04 |h 297-305 | ||